Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2b Study of ASP015K - A Double-Blind, Placebo-Controlled, Dose-Finding Study in Moderate to Severe Rheumatoid Arthritis Patients

NCT01649999 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT01649999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01649999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2b Study of ASP015K - A Double-Blind, Placebo-Controlled, Dose-Finding Study in Moderate to Severe Rheumatoid Arthritis Patients
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
March 1, 2012
Completion date
July 20, 2013
Enrollment
281 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid